Ensysce Biosciences (NASDAQ:ENSC) Posts Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Ensysce Biosciences (NASDAQ:ENSC) released its quarterly earnings data on Tuesday. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.37, Zacks reports. Ensysce Biosciences had a negative return on equity of 559.68% and a negative net margin of 179.26%. The firm had revenue of $3.42 million during the quarter, compared to the consensus estimate of $0.25 million.

Ensysce Biosciences Stock Performance

NASDAQ:ENSC opened at $0.68 on Thursday. The firm has a 50-day simple moving average of $0.36 and a 200-day simple moving average of $0.45. Ensysce Biosciences has a one year low of $0.14 and a one year high of $2.06. The firm has a market cap of $5.95 million, a P/E ratio of -0.39 and a beta of 0.63.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.